BeOne Medicines (ONC) has drawn investor attention after its rebrand from BeiGene, Ltd. to BeOne Medicines AG in May 2025. The change highlights a broad oncology portfolio across commercial, clinical, and preclinical cancer therapies.

After the rebrand, BeOne Medicines’ share price has been under pressure in the short term, with a 7 day share price return of a 15.18% decline and a 30 day share price return of a 7.64% decline. Its 1 year total shareholder return of 28.03% and 3 year total shareholder return of 31.73% suggest that longer term holders have seen positive results.

If this oncology update has you thinking more broadly about healthcare opportunities, you might want to scan our screener of 28 healthcare AI stocks as a starting point for your research.

With the share price recently under pressure yet trading at what some models suggest is a sizeable intrinsic discount, investors are left with a key question: is BeOne Medicines an overlooked oncology powerhouse, or is the market already pricing in future growth?

Most Popular Narrative: 22.2% Undervalued

BeOne Medicines last closed at $314.36 compared with a widely followed fair value estimate of $404.19, which frames the current debate around its oncology pipeline.

BeOne's strong revenue growth (41% YoY in Q2; updated full-year guidance of $5 to $5.3B) is underpinned by rapid demand expansion for differentiated, best-in-class oncology therapies like BRUKINSA, supported by a growing, aging population and increased global healthcare spending, both of which point to a sustainably expanding addressable market and future revenue growth.

Read the complete narrative. Read the complete narrative.

Curious what underpins that higher fair value? The narrative leans on rising earnings power, expanding margins and a richer future profit multiple than the sector typically commands.

Result: Fair Value of $404.19 (UNDERVALUED)

However, this upbeat narrative can quickly unravel if late stage trials disappoint or if heavy reliance on BRUKINSA and the CLL franchise leads to sharp revenue swings.

Another Angle On Valuation

Here is the tension. Our model flags BeOne Medicines as trading at a 65% discount to its estimated future cash flow value of $897.98 per share, using the SWS DCF model. However, the current price of $314.36 already implies a P/E of 121.5x. Which signal do you trust more: optimistic cash flows or today’s earnings multiple?

Next Steps

If this mix of optimism and caution feels familiar, stay close to the numbers, form your own view quickly, and check out 4 key rewards.

Looking for more investment ideas?

Do not stop with a single stock. Broaden your watchlist using focused stock lists that surface different kinds of opportunities other investors might be overlooking.

• Target potential value opportunities by scanning our list of 45 high quality undervalued stocks that pair strong fundamentals with pricing that some investors may have overlooked.
• Build a sturdier core to your portfolio by screening for companies in our solid balance sheet and fundamentals stocks screener (41 results) that keep leverage in check and finances in order.
• Hunt for tomorrow’s potential standouts before the crowd notices by reviewing the screener containing 24 high quality undiscovered gems backed by solid underlying business metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.